Sorivudine: A Potent Inhibitor of Varicella Zoster Virus Replication
Effective antiviral therapy has been achieved with the administration of nucleoside analogs, particularly for herpesvirus and human immunodeficiency virus infection. Compounds such as acyclovir, ganciclovir, and penciclovir are prototype nucleoside analogs which have demonstrated antiviral activity against several members of the herpesvirus family. Sorivudine (bromovinyl arabinosyl uracil; BVarak) is a relatively new nucleoside analog which was synthesized by Dr. Machida of the Yamasa Shoyu Company in Japan.1,2 Sorivudine has undergone field trial evaluation for the treatment of zoster in Japanese volunteers and was licensed for the treatment of this disease in 1994 in that country. Currently, the compound is under evaluation in the United States, Canada, Europe, and Australia for the treatment of varicella zoster virus (VZV) infections in both the normal and immunocompromised host. This review will briefly summarize published data on sorivudine and its potential as a therapeutic for VZV infections.
KeywordsHuman Immunodeficiency Virus Herpes Zoster Thymidine Kinase Varicella Zoster Virus Nucleoside Analog
Unable to display preview. Download preview PDF.
- 6.Yokota T, Kono K, Mori S, Shigeta S, Kumagai M, Watanabe Y, Machida H. Mechanism of selective inhibition of varicella-zoster virus replication by 1-b-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil. A report from Yamasa Shoyu Co., Japan, 1988Google Scholar
- 8.Whitley RJ, Weiss H, Gnann J, et al. Sorivudine (BV-araU) versus acyclovir for herpes zoster in HIV-infected patients: Results of a multi-center controlled trial. Presented at the Clinical Research Meeting. San Diego, CA, May 5–8, 1995. J Invest Med 1995; 43: A114.Google Scholar
- 9.Wallace MR, Sawyer MH, Chamberlin CJ, Hawkins J, Oldfield III EC. BV-aru-U for the treatment of adult varicella. Presented at the Second International Conference on Varicella Zoster Virus Infections. Paris, France. 1994, July 7 and 8.Google Scholar
- 10.DeHertog D, et al. Sorivudine (BV-araU) versus acyclovir for herpes zoster in HIV-infected patients: Results of a multi-center controlled trial. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, Florida, October 4–7, 1994. Late breaker.Google Scholar